Merck (MRK) Tops Q3 EPS by 20c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Merck (MRK) PT Raised to $90 at Morgan Stanley on Gardasil Strength
October 29, 2021 8:46 AM EDTMorgan Stanley analyst Matthew Harrison raised the price target on Merck (NYSE: MRK) to $90.00 (from $88.00) while maintaining a Equalweight rating after 3Q total revenue beat expectations driven primarily by Gardasil sales due to strong global demand and increased supply. Management expects robust... More
